Denovo Biomarkers: Robert Little. Providing a novel biomarker solution to personalize drug development




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Denovo Biomarkers: Robert Little. Providing a novel biomarker solution to personalize drug development
Released on: July 03, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Robert Little, the Chief Business Officer of Denovo Biomarkers reveals to Fintan Walton the use of its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.
  • Summary
  • Transcript
  • Participants
  • Company
Robert Little, the Chief Business Officer of Denovo Biomarkers reveals to Fintan Walton the use of its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.
Robert Little, the Chief Business Officer of Denovo Biomarkers reveals to Fintan Walton the use of its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.
Robert Little
Denovo Biomarkers
Denovo Biomarkers
Denovo Biomarkers is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effect. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in targeted patient population to achieve higher efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in most therapeutic areas, such as oncology, metabolic, cardiovascular, immunological, and neurological diseases.